Edition:
United Kingdom

People: Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

5.55USD
7:42pm BST
Change (% chg)

$-0.03 (-0.45%)
Prev Close
$5.58
Open
$5.61
Day's High
$5.61
Day's Low
$5.51
Volume
133,702
Avg. Vol
265,712
52-wk High
$8.05
52-wk Low
$4.49

Moore, Timothy 

Mr. Timothy L. Moore is Independent Director of the Company. Mr. Moore has served as a member of our Board since September 2018, filling the vacancy left by our former director, Bruce Cozadd. Mr. Moore is currently Executive Vice President, Technical Operations of Kite Pharma, a Gilead Company. Prior to Kite, he spent more than 12 years at Genentech, a Roche Company, most recently as Senior Vice President, Head of Global Technical Operations – Biologics and a member of the Genentech Executive Committee. While at Genentech, he oversaw global leadership for more than 7,500 professionals across 10 internal sites and managed more than 30 contract manufacturing organizations, including end to end quality supply performance of more than 20 biological products. Mr. Moore is currently a member of the board of directors FusionKite, a joint venture between Gilead Sciences, Inc. and Fusion Pharmaceuticals Inc. He holds a Bachelor of Science, Chemical Engineering from Tulsa University and an M.S. from Northwestern University.

Basic Compensation

Total Annual Compensation, USD 14,826
Restricted Stock Award, USD 87,259
Long-Term Incentive Plans, USD --
All Other, USD 96,929
Fiscal Year Total, USD 199,014

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Daniel Swisher

252,996

William Greenman

2,983,440

Kevin Green

1,022,270

Carol Moore

981,744

William Moore

--

Laurence Corash

1,040,260
As Of  31 Dec 2018